Jefferies Assumes AcelRx Pharmaceuticals (ACRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Roth Capital Starts AcelRx Pharmaceuticals (ACRX) at Buy
April 14, 2014 8:11 AM EDTRoth Capital initiated coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $10.32 yesterday.
... More